Editas Medicine

Update in progress

EDIT (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Editas Medicine, Inc. is a clinical‑stage genome editing company developing genomic medicines for serious diseases using a CRISPR‑based platform. Its lead program, EDIT‑401, is a one‑time therapy aimed at lowering LDL cholesterol by upregulating LDL receptors. The company also targets sickle cell disease and transfusion‑dependent beta thalassemia, with in vivo editing programs and a Juno Therapeutics collaboration on alpha‑beta T‑cell therapies for cancer and autoimmune diseases. Based in Cambridge, Massachusetts, it was formerly Gengine, Inc., renamed in 2013.

Company score

Sentiment: -0.19; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive